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There has been an increase in clinical trial litigation in the last 
few years both in South Africa (SA) and abroad, with plaintiffs 
suing various role players – including research sponsors, institutions 
and investigators.[1-4] This has highlighted the need for a legally 
effective clinical trial agreement (CTA) to be concluded between 
the various parties prior to the commencement of a clinical trial. 
The CTA should describe and acknowledge responsibilities, terms 
of collaboration, requirements for payment and reimbursement, 
publication and intellectual property terms, indemnification and/or 
insurance, subject injury coverage, guidelines for dispute resolution, 
grounds for termination of contract and the possibility of amending 
contract terms in the future.[1] In addition, the CTA should protect the 
participant, sponsor and investigator.
In recent years, global human research protection programmes 
(HRPPs) have put steps in place to minimise contract ambiguity 
and cause for litigation. One such example is the Association for the 
Accreditation of Human Research Protection Programs (AAHRPP), 
which promotes high-quality, ethically sound research through an 
accreditation process that helps organisations worldwide strengthen 
their HRPPs.[5]
An independent, non-profit accrediting body, AAHRPP uses a 
voluntary, peer-driven, educational model to ensure that HRPPs meet 
rigorous standards for quality and protection. To earn accreditation, 
organisations must provide tangible evidence – through policies, 
procedures, and practices – of their commitment to scientifically and 
ethically sound research, and to continuous improvement.[6] 
As the ‘gold seal’, AAHRPP accreditation offers assurances – to 
research participants, researchers, sponsors, government regulators 
and the public – that an HRPP is focused first and foremost on 
excellence.[6] 
In accordance with AAHRPP, the following statements need to be 
included in the CTA: 
‘(i)  The sponsor and/or its representative will be responsible for costs 
of medical care [if ] a participant suffers a research-related injury. 
(ii)  The sponsor and/or its representative is/are obligated to 
promptly report to the Organisation any findings that could: 
 a. affect the safety of participants 
 b. influence the conduct of the study. 
(iii)  The sponsor and/or its representative is/are obligated to 
promptly send the organisation all data and safety monitoring 
plans and reports. 
(iv)  The sponsor and/or its representative is/are obligated to 
promptly communicate findings from any research study, even 
after its closure, when those findings could directly affect the 
safety of participants.’[5] 
In this study, we aimed to analyse whether CTAs from various 
sponsors met these minimum requirements. 
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Introduction. Increasing numbers of litigation cases in clinical research highlight the need for definitive and transparent clinical trial 
agreements (CTAs). The requirements set by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) are 
an attempt to minimise miscommunication between sponsor and site, and promote human research protection. These requirements 
include: (i) the obligation of the sponsor and/or its representative to communicate study results; (ii) the obligation of the sponsor and/or its 
representative to promptly report any findings that could affect the participants’ safety and/or influence study conduct; and (iii) the sponsor’s 
liability for the cost of medical care in the event of a research-related injury.
Objective. To analyse 40 CTAs as to which of the AAHRPP requirements they met.
Methodology. Forty consecutive CTAs signed by our institution, with 15 different research sponsors, were analysed and tracked as to which 
AAHRPP criteria they met. 
Results. No CTAs complied with all the AAHRPP requirements. Notably, 17.5% stipulated that the sponsor would communicate study results, 
but none stipulated that it would directly inform the site of these results; 35% stated that the sponsor would be responsible for reporting any 
findings/additional information that might affect participants’ safety and/or influence the conduct of the study; and 40% explicitly stipulated 
that the sponsor was obliged to pay for the cost of patients’ medical care in the event of a research-related injury. 
Conclusions. The AAHRPP requirements are an attempt to minimise miscommunication between sponsor and site, yet most CTAs fail to 
stipulate what should be fundamental requirements of every contract. 
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Methodology 
Forty consecutive CTAs that were signed by our institution, with 15 
different SA-based research sponsors, were analysed as to which 
AAHRPP criteria they met. All studies analysed were cardiovascular 
research studies. These 40 CTAs were signed between May 2013 and 
February 2016. The analysis took place during March - May 2016. 
The CTAs were listed in a table format, and individually tracked 
by a single rater as to which of the following criteria they met, by 
including:
• a statement discussing the obligation of the sponsor to 
communicate study results
• a statement discussing the obligation of the sponsor to report 
findings that may affect participant safety/influence study conduct 
• a statement discussing the obligation of the sponsor to send data 
and safety-monitoring reports 
• a statement that the sponsor and/or its representative will be 
responsible for costs of medical care if a participant were to suffer 
a research-related injury 
• an insurance certificate
• indemnification of the research site
• a statement in the informed consent form that the Association of 
the British Pharmaceutical Industry (ABPI) compensation guidelines 
will be followed. 
All 40 trials had been approved by the SA Medicines Control Council 
(MCC) and the Stellenbosch Health Research Ethics Committee 
(HREC). It should be noted that as per AAHRPP regulations, containing 
any of the above requirements in the informed consent forms does 
not absolve the clinical trial agreement from also needing to include 
them (apart from the statement that ABPI guidelines would be 
followed). Also, stating that the trial will be carried out as per good 
clinical practice guidelines does not secondarily fulfil any of the 
above criteria. 
This study did not involve research participants, as it is an analysis 
of our own records, which are kept confidential. Therefore, ethics 
approval was not necessary. 
Results 
None of the CTAs demonstrated compliance with all the AAHRPP 
requirements. CTAs are becoming longer and more complex, yet the 
onus remains on the clinical trial sites to comply with them[7] – more 
obligations are being assigned to sites, while sponsor obligations are 
overlooked, as demonstrated below. This is especially prevalent in the 
reporting of safety issues and the communication of study results, as 
seen in Fig. 1. 
Only 17.5% of contracts analysed in this study stipulated that 
the sponsor would communicate study results, and of these, none 
stipulated that it would directly inform the site of these results. They 
merely stated that the results would be released publically, meaning 
that the busy site would have to follow up themselves. Sponsors 
seem overly concerned with sites first obtaining permission to 
publish study results, and most fail to mention their own obligation 
to share study results. 
Only 35% of contracts stated that the sponsor would be responsible 
for reporting any findings/additional information that may affect 
participant safety or influence the conduct of the study. And only 15% 
of contracts acknowledged the sponsor’s responsibility to share data 
and safety monitoring reports with the site. Only 40% of clinical trial 
agreements explicitly stipulated that the sponsor was obliged to pay 
for the cost of the patients’ medical care. An encouraging finding from 
the study is that 100% of contracts contained insurance certificates, 
and 97.5% contained statements covering indemnification of the 
research site. Additionally, every contract’s corresponding informed 
consent form (ICF) contained a statement that ABPI compensation 
guidelines would be followed. Overall, out of the 280 criteria analysed 
(7 × 40 CTAs), 162 were met, giving a general completion rate of 
58.86%. 
Discussion 
Sponsors’ obligation to communicate study 
results with the study site 
Of the 40 CTAs reviewed, only 7 (17.5%) of the contracts stated 
that the sponsor was obligated to communicate the study results. 
Furthermore, this was invariably an obligation to the sites and not to 
the actual trial participants themselves.[8] 
These results are made more pertinent by the recent European 
Union (EU) regulations, which dictate that a lay language summary of 
study results must be made available to study participants, irrespective 
of the study outcome.[8] The EU states that this summary must include: 
• clinical trial identification
• name and contact details of the sponsor
• main objectives
• population of subjects (including eligibility criteria)
• investigational medicinal products used
• description of adverse events and frequency
• overall results of the clinical trial
• comments on the outcome of the clinical trial
• information as to whether follow-up clinical trials are foreseen
• information on where additional information can be found.[9]
Given that these EU regulations were implemented in 2016, it is 
concerning that such a low number of contracts made mention 
of this obligation. It is important to communicate study results to 











































































































































Fig. 1. Prevalence of each AAHRPP criterion in CTAs (N=40). 
(AAHRPP  =  Association for the Accreditation of Human Research 
Protection Programs; ABPI = Association of the British Pharmaceutical 
Industry; CTA = clinical trial agreement.)
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seen as ‘human guinea pigs’ remains; therefore it is vital for the 
industry to be as transparent and trustworthy as possible, to move 
towards shifting public perception away from such myths.[10] The 
2015 Center for Information & Study on Clinical Research Participation 
(CISCRP) Report on Participation Experiences[11] conducted a study in 
which approximately 12 000 participants of clinical trials worldwide 
completed surveys pertaining to their experiences. Of these, 90% of 
participants want to know the results of their clinical trial, 91% had 
never heard back from the study staff or sponsor, and 68% would not 
participate in future trials if left uninformed.[11] These results portray 
the considerable number of patients who are never informed about 
the results of their trial, and highlight the importance of keeping 
participants informed, as it is often mistakenly taken for granted that 
they ‘are not interested.’ 
There is also the ethical obligation to communicate study results 
to participants, as it is fundamentally the ‘right thing to do’ and helps 
build patients’ trust and satisfaction with their clinical trials.[8] Many 
participants finish their trials and remain unaware of the study results 
indefinitely, as they are simply not communicated to them.
Sponsors’ obligation to share current study safety 
data with the research site 
Only 15% of CTAs stated that the sponsor was obligated to send data 
and safety monitoring reports to the site. Furthermore, only 35% of 
these CTAs stated that the sponsor was obligated to report findings 
that may affect participants’ safety and/or influence study conduct. 
This may have a negative effect on sites’ ability to communicate 
results to participants and, more importantly, their ability to protect 
the participant legally, ethically, and physically. 
While it is true that sponsors, in the research site’s own experience, 
do usually communicate this information through safety letters, 
weekly reports, etc., the lack of a legal obligation to do so can lead to 
intentionally hidden or misrepresented data being communicated. 
Sponsors may choose to do this in order to deceive investigators into 
carrying on with the study, and also to make the results ‘look better’ 
in order to have their product approved and bring it to shelves. While 
extremely unethical, these sorts of practices have occurred in the 
past, such as with the Vioxx fiasco.[12]
Vioxx (rofecoxib) was introduced in 1999 by Merck as an effective, 
safer alternative to non-steroidal anti-inflammatory drugs for 
treating osteoarthritis pain.[12] The drug was found to raise the risk 
of developing cardiovascular disease, and eventually withdrawn 
from market. However, there is evidence that early suspicion of 
cardiovascular risk existed as well as deliberate obscuring of data 
in order to downplay these risks and promote the efficacy of the 
drug, in order to bring it to market. Since early development, 
some scientists at Merck were concerned that the drug may affect 
the cardiovascular system by altering the ratio of prostacyclin to 
thromboxane, which act in opposition, balancing blood flow and 
clotting.[12] From internal emails there is evidence that Merck sought 
to soften academic authors’ interpretation that the drug might 
lead to increased thrombus formation. Yet despite this knowledge, 
none of the early intervention studies were designed to evaluate 
the drug’s cardiovascular risk. Instead, data were pooled and results 
circulated to promote the drug’s safety to doctors through Merck’s 
‘cardiovascular card,’ a non-FDA (Food and Drug Administration)-
approved marketing tool.[12] 
There is evidence of deliberate obscuring of data to downplay the 
cardiovascular risks. An interim analysis of the drug’s VIGOR study 
changed the termination dates for cardiovascular event reporting 
in order to exclude three events of myocardial infarction. The 
termination date for gastrointestinal events remained the same, 
with results favouring the drug’s effect on gastrointestinal events 
while understating the risk of cardiovascular events.[12] The data were 
further concealed by Merck using naproxen (the comparator drug) 
as the intervention group for presenting the hazard of myocardial 
infarction, even though all other results were properly presented 
with rofecoxib as the comparator. By presenting the information in 
this manner, Merck argued that naproxen increased cardiovascular 
protection (despite no evidence of this), rather than Vioxx increasing 
cardiovascular risk.[12] Merck has since voluntarily withdrawn Vioxx, 
but has upwards of 30 000 legal claims from people who suffered 
cardiovascular events while taking the drug, which Merck denies 
liability for.[12] 
The withholding of (or tampering with) safety data can have 
resonating repercussions for the participant, sponsor and, by 
extension, the site. It highlights the importance of transparency 
when conducting clinical research, and the need to communicate 
the safety data. 
Obligation to cover the costs of medical care 
Only 40% of the CTAs explicitly stated that the sponsor and/or its 
representative would be responsible for the cost of medical care if a 
participant were to suffer a research-related injury. The importance 
of this is highlighted by the fact that clinical trial sites have been 
exploited by patients and sponsors alike, owing to contracts not 
being explicit enough. A recent case that drew attention in the SA 
clinical trial industry was Venter v Roche Products (Pty) Limited and 
Others. In this case the Western Cape High Court had to adjudge 
whether the plaintiff, Mr Venter, was due additional compensation 
for non-medical costs such as pain and suffering, loss of income and 
general damages, even though Mr Venter had signed an ICF which 
expressly excluded such claims.[3] 
This ICF stated that the sponsor would pay only for the cost of any 
trial-related medical treatment the participant may have undergone, 
and that any further claims for compensation would be determined 
using the ABPI compensation guidelines. Mr Venter suffered a 
research-related injury and hospitalisation, and it was as a result of 
this incident that the plaintiff claimed to have suffered damages.[3] 
Upon review of the aforementioned ICF and the ABPI guidelines, it 
was determined that there was no legal obligation for compensation 
to be paid beyond the medical costs incurred. It must also be noted 
that the court took into consideration the fact that such studies and 
their corresponding documents undergo expert legal and ethical 
review by the MCC and research ethics committees before being 
approved. The court accepted that limiting compensation in this 
way was reasonable, as these regulatory committees had the legal 
authority to approve or not approve such research.[3] Therefore, in 
light of the arguments above, the court dismissed the case.[3] 
Many of the clinical trials in SA form part of multinational trials that 
take place at numerous sites across the world. The parent company 
sponsor for these trials is rarely South African, and as such, the original 
CTAs are drafted in countries with different health practices and laws 
to SA’s. Contracts are amended to suit the trial country; however, 
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sometimes the differences are not fully realised and implemented, 
and ambiguity and exclusion of necessary information can occur. 
An example of this would be difference between SA and the 
USA with regard to remunerating health research participants. US 
contracts typically state that were a patient to suffer a research-related 
injury, they would pay above what healthcare covers, whereas in SA 
participant remuneration is determined using the aforementioned 
ABPI compensation guidelines. It is promising that 100% of the 
reviewed ICFs contained statements that ABPI guidelines would be 
followed.
Specific compensation guidelines are vital for cases such as the 
2010 India incident. Of the 25 people who suffered trial-related 
deaths in India in 2010, only 5 of the families had been compensated 
an amount of INR1.5 - 3 lakh (approximately ZAR30 000 - 60 000 at 
the time).[13] The Drug Controller General of India summoned the 
nine pharmaceutical companies responsible to question them on the 
compensatory amount (determined by the companies’ internal ethics 
committees), and ordered them to pay all compensation or risk any 
future trials being disallowed. As a direct reaction to this incident, 
in 2011, the Indian Council of Medical Research drafted official 
compensation guidelines for participants suffering research-related 
injuries in India.[13] 
Conclusion 
With the increasing number of litigation cases in clinical research, 
both locally and abroad, there is a growing need for definitive and 
transparent clinical trial agreements.[3,4] Clearly defined roles for both 
sponsor and site would help to reduce ambiguity and confusion 
between the two. The AAHRPP requirements are an attempt to 
minimise miscommunication between sponsor and site, yet as this 
study shows, a worrying number of CTAs fail to stipulate what should 
be fundamental requirements of every contract. 
Of the 40 CTAs reviewed, only 7 (17.5%) of the contracts stated 
that the sponsor was obligated to communicate the study results. 
Furthermore, this was invariably an obligation to the sites, and not 
to the actual trial participants themselves. These results are made 
more pertinent by the EU regulations dictating that a lay language 
summary of study results must be published to study participants, 
irrespective of the study outcome.[9] And as shown through the 
CISCRP study, patients do want to be informed about the results of 
their trials.[11] Only 15% of CTAs stated that the sponsor was obligated 
to send data and safety-monitoring reports to the site. Furthermore, 
only 35% of these CTAs stated that the sponsor was obligated to 
report findings that may affect participant safety and/or influence 
study conduct. This may have a negative effect on sites’ ability to 
communicate results to participants and, more importantly, their 
ability to protect the participant legally, ethically and physically. 
Only 40% of the CTAs explicitly stated that the sponsor and/or its 
representative would be responsible for the cost of medical care were 
a participant to suffer a research-related injury. The importance of this 
is highlighted by the fact that clinical trial sites have previously been 
exploited by patients and sponsors alike, as a result of insufficiently 
explicit contracts.[3] 
Further research of this nature could be useful in addressing this 
study’s limitations. For example, more clinical research sites could 
conduct similar studies, and multiple raters could be used to improve 
reliability. 
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